MTWA is a marker of Sudden Cardiac Arrest (SCA) risk which is measured during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies.
Cambridge Heart CEO Ali Haghighi-Mood said they look forward to gaining regulatory approval in Singapore, which they expect will occur within the next six to nine months, and begin marketing their MTWA technology.
